[New oral anticoagulants: pharmacological data to know for clinical practice].


New oral anticoagulants target specific factors in the coagulation cascade by directly inhibiting thrombin for dabigatran and Factor Xa for -xatrans. Pharmacological progresses with these anticoagulants allow the use of fixed doses without any therapeutic drug monitoring. Their pharmacokinetic specificity is the key role of the transporter proteins P-glycoprotein (P-gp) for all these drugs and the metabolism mediated by CYP3A4 for -xabans. Dose adjustment is recommended for decreasing creatinine clearance or in case of drug-drug interaction. New oral anticoagulants are promising but their safety needs further investigations in particular populations such as elderly patients, patients with renal or hepatic impairment, or patients on polymedication.

Cite this paper

@article{Delavenne2014NewOA, title={[New oral anticoagulants: pharmacological data to know for clinical practice].}, author={Xavier Delavenne and Silvy Laporte and Patrick Mismetti}, journal={Revue médicale suisse}, year={2014}, volume={10 416}, pages={319-24} }